Publications by authors named "Marco Bellero"
This study explores the potential use of ChatGPT, an AI-based language model, in assessing herbal-drug interactions (HDi) to enhance clinical decision-making. HDi can pose significant health risks by reducing drug efficacy or causing unwanted side effects. Clinical pharmacists play a key role in identifying these HDIs, and currently, there are limited tools available for checking drug interactions.
View Article and Find Full Text PDFPurpose: Oral metronomic cyclophosphamide (OMC) implicates the daily administration of low doses of chemotherapy. Its antitumor activity combined with an oral administration route and a good toxicity profile makes OMC an attractive option for heavily pretreated patients. We retrospectively evaluated OMC's clinical benefit and objective response in recurrent ovarian cancer patients.
View Article and Find Full Text PDFArticle Synopsis
- Cemiplimab, an antibody targeting the PD-1 receptor, is being evaluated in a real-world study in Italy for patients with advanced cervical cancer who have undergone platinum-based chemotherapy, following promising initial trial results.
- The study involved 135 patients, assessing primary outcomes like progression-free survival (PFS) and overall survival (OS), along with safety and response rates to treatment.
- Results showed a median PFS of 4 months and median OS of 12 months, with anemia and fatigue being the most common side effects, highlighting the treatment's feasibility in clinical practice.
Introduction: Low molecular weight heparin (LMWH) has been the backbone of the treatment of cancer associated thrombosis (CAT). Direct-acting oral anticoagulants (DOACs) have shown efficacy and safety not inferior to LMWH and guidelines included DOACs as an option for CAT treatment. Nevertheless, DOACs are still poorly prescribed in patients with cancer.
View Article and Find Full Text PDF